ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Entrada Therapeutics (TRDA) pipeline and stated timing

Name in SEC filings: Entrada Therapeutics, Inc.

Pipeline at a glance

ProgramEventStageStated timingFiling
ENTR-601-45/data readoutStage not statedOctober 202610-Q ·
ENTR-601-44Topline/data readoutStage not statedby year-end 20268-K ·

Source: ORION, orionbiotechai.com/company/TRDA, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/TRDA

Nearest upcoming stated timing: ENTR-601-44 · Topline/data readout · by year-end 2026

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

ENTR-601-44

Matched

Topline/data readoutby year-end 2026

Stage: Not stated

Public float: $191,200,000 · as of · SEC filing

The Company is on track to report data from the Cohort 1 (6 mg/kg) open-label period of the study by year-end 2026.

8-K · Filed · Last checked

Source details

Accession 0001689375-26-000052

Alert me · Calendar: same stage and window-end month (2026-12)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
ENTR-601-44Clinical resultsby year-end 2026
“The Company is on track to report data from the Cohort 1 (6 mg/kg) open-label period of the study by year-end 2026.”

Filed · EX-99.1

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

ENTR-601-45Clinical resultsOctober 2026
“We expect to report our Cohort 1 ELEVATE-45-201 multiple ascending dose ("MAD") data in October 2026.”

Filed · 10-Q

Disclosure present

SEC filing date within the stated period

Filed · 8-K

“On October 14, 2026, the Company announced positive topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of the Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45 in ambulatory participants with a confirmed mutation in the DMD gene amenable to exon 45 skipping.”

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Retained program pages

Watch TRDA

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for TRDA. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See TRDA in the calendar · Review labels and methodology

Topline results are the main summary results of a clinical trial, released before the full data.